Onvansertib
As of the edition of 20 October 2026, Onvansertib is a small molecule: in active development; acts on PLK1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 14, 1 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Blood and lymph; Lungs and airways; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PLK1 | Serine/threonine-protein kinase PLK1 | P53350 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 1 | 2 | 0 |
| Phase 2 | 10 | 5 | 4 | 1 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Nerviano Medical Sciences | Lead sponsor of trials | 2009 to now |
| Cardiff Oncology | Lead sponsor of trials | 2021 to now |